Tirzepatide vs Semaglutide: A Detailed Comparison
Head-to-head comparison of tirzepatide and semaglutide for weight loss and diabetes, including clinical trial data, side effects, costs, and which one might be right for you.
Tirzepatide and semaglutide are the two most prescribed GLP-1-based medications for weight loss. While they share similarities, important differences in mechanism, efficacy, and side effects set them apart.
Mechanism of Action
Semaglutide is a pure GLP-1 receptor agonist. It mimics the natural GLP-1 hormone, activating one receptor pathway.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone that, when combined with GLP-1 activity, appears to produce additive metabolic benefits.
A 2022 review in Nature Reviews Endocrinology explained that dual agonism may enhance weight loss through additional effects on fat tissue metabolism and energy expenditure beyond what GLP-1 alone provides (Samms et al., 2022).
Weight Loss: Head-to-Head
The SURMOUNT-5 trial directly compared tirzepatide and semaglutide for weight loss (results presented 2024):
| Metric | Tirzepatide 15mg | Semaglutide 2.4mg |
|---|---|---|
| Mean weight loss | ~20.2% | ~13.7% |
| Participants losing >15% | ~71% | ~47% |
| Participants losing >20% | ~52% | ~28% |
This was the first head-to-head comparison and confirmed tirzepatide's superiority for weight loss.
Earlier indirect comparisons told a similar story:
- SURMOUNT-1 (tirzepatide): Up to 22.5% weight loss
- STEP 1 (semaglutide): 14.9% weight loss
Blood Sugar Control
For type 2 diabetes, the SURPASS-2 trial directly compared tirzepatide to semaglutide 1mg:
- Tirzepatide reduced HbA1c by 2.0-2.3% (depending on dose)
- Semaglutide 1mg reduced HbA1c by 1.9%
- More tirzepatide patients achieved HbA1c below 5.7% (normal range)
Cardiovascular Benefits
Semaglutide currently has stronger cardiovascular evidence:
- The SELECT trial (2023) demonstrated a 20% reduction in major cardiovascular events with semaglutide in overweight/obese adults without diabetes
- Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing, with results expected in 2026-2027
Side Effect Comparison
| Side Effect | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea | 24-33% | 44% |
| Diarrhea | 17-23% | 30% |
| Vomiting | 9-13% | 25% |
| Constipation | 6-12% | 24% |
| Discontinuation rate | ~6% | ~7% |
Data from respective Phase 3 trials. Rates vary by dose.
Overall, tirzepatide's GI side effect profile may be slightly more favorable, possibly due to the GIP component's effects on the gut.
Dosing Comparison
| Tirzepatide | Semaglutide | |
|---|---|---|
| Route | Subcutaneous injection | Subcutaneous injection |
| Frequency | Weekly | Weekly |
| Starting dose | 2.5mg | 0.25mg |
| Dose escalation | Every 4 weeks | Every 4 weeks |
| Max dose (weight loss) | 15mg | 2.4mg |
| Max dose (diabetes) | 15mg | 2.0mg |
Cost Comparison
| Tirzepatide | Semaglutide | |
|---|---|---|
| Weight loss brand | Zepbound | Wegovy |
| Diabetes brand | Mounjaro | Ozempic |
| Monthly list price (weight loss) | ~$1,060 | ~$1,349 |
| Manufacturer savings available | Yes | Yes |
For a detailed cost breakdown, see our GLP-1 cost guide.
Which One Should You Choose?
Choose tirzepatide if:
- Maximum weight loss is your primary goal
- You want potentially fewer GI side effects
- Your insurance covers Zepbound or Mounjaro
Choose semaglutide if:
- Cardiovascular risk reduction is important to you
- You prefer a medication with the longest evidence base
- Your insurance covers Wegovy or Ozempic
- You want the option of an oral formulation in the future
Important: Both medications are excellent options backed by robust clinical evidence. The "best" choice is the one your doctor recommends based on your specific health profile, and that your insurance will cover.
The Bottom Line
Tirzepatide produces more weight loss on average, while semaglutide has broader cardiovascular evidence. Both are injected weekly, have similar side effect profiles, and are FDA-approved for weight management. Work with your healthcare provider and check your insurance formulary to make the right choice for you.
Track whichever medication you choose with GLP Pal to stay on schedule and monitor your progress.